BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:27 PM
 | 
Feb 11, 2016
 |  BC Extra  |  Clinical News

Incyte discontinues Jakafi trials in solid tumors

Incyte Corp. (NASDAQ:INCY) reported 4Q15 and 2015 revenues that beat expectations but fell $6.80 to $65.51 on Thursday after it said it would discontinue all ongoing trials of myelofibrosis drug Jakafi ruxolitinib in solid tumors, including the Phase III JANUS 1 and JANUS 2 trials of Jakafi plus Xeloda capecitabine as a second-line therapy for advanced or metastatic pancreatic cancer.

The biotech said a planned interim analysis of JANUS 1 "did not show a sufficient level of efficacy to warrant continuation," following a...

Read the full 423 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >